Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment

Inclusion Criteria: * Patient age ≥ 18 years * Performance Status WHO \< 2 * Initially treated for Epithelial Ovarian Carcinoma * Patient with only peritoneal relapse occurred at least 6 month from the initial treatment, resectable without distant metastasis (with the exception of communicating pleura effusion, sensitive to platine-based second line chemotherapy and resectable lymph-nodes in the groin or retro peritoneal) * Platinum based second-line chemotherapy before surgery with either carboplatine-paclitaxel, or carboplatine-caelyx * Complete cytoreductive surgery * The surgery has to be planned 5 to 8 weeks from the last 2nd of chemotherapy * No hepatic failure, bilirubin ≤ 1,5 time the Normal limit, ASAT and ALAT ≤ 3 time the Upper Normal Limit * No Renal insufficiency (serum creatinine \< 1,5 time the normal limit, creatinine clearance \> 80 mL/min). calculated with MDRD method * Hematology function: PNN ≥ 1,5x10⁹/L, platelets ≥ 100x10⁹/L * No contraindication to general anaesthesia for heavy surgery * Patients having read, signed and dated Informed consent before any study procedure * Childbearing patients have to take appropriate contraceptive methods during the treatment and until 6 months after the treatment Exclusion Criteria: * Patient age \<18 years * Previous cancer in the last 5 years (except cutaneous baso-cellular epithelioma or uterine peripheral epithelioma) * Hypersensitivity to Platinum compound * Distant metastasis * Use of anti-angiogenic treatment * Patient with other concurrent severe life threatening disease * The need to perform more than two segmental digestive resections during the CRS +/- HIPEC surgery * Any progressive disease during the IV systemic second-line chemotherapy (platine-based) * Incomplete cytoreductive surgery with macroscopical residual disease (Sugarbaker \> CC1) * Early relapse: less than 6 mois after the end of the first treatment * Ovarian tumor other than Epithelioma Ovarian Cancer * Uncontrolled infection * Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Clinically significant cardiovascular disease contraindicating the hyper hydratation, which is necessary for HIPEC * Patient already treated with HIPEC for the ovarian cancer * Individual deprived of liberty or placed under the authority of a tutor